Synuclein Motor Dysfunction Composite Scale for the Discrimination of Dementia With Lewy Bodies From Alzheimer's Disease

Overview

Journal Front Aging Neurosci

Specialty Geriatrics

Date 2022 Jun 6

PMID 35663565

Authors

Ying-Tsung Chen

Satoshi Orimo

Cheng-Yu Wei

Guang-Uei Hung

Shieh-Yueh Yang

Pai-Yi Chiu

Affiliations

Soon will be listed here.

Abstract

Background: An abnormal increase of α-synuclein in the brain is the hallmark of dementia with Lewy bodies (DLB). However, the diagnostic power of plasma α-synuclein in DLB is not yet confirmed. Parkinsonism is highly associated with and is one of the core clinical features of DLB. We studied plasma α-synuclein and developed a novel tool that combined plasma α-synuclein level and Motor Dysfunction Questionnaire (MDQ), namely Synuclein Motor Dysfunction Composite Scale (SMDCS), for the clinical discrimination of DLB from Alzheimer's disease (AD).

Methods: This cross-sectional study analyzed participants' demographical data, plasma α-synuclein level, MDQ, structured clinical history questionnaire, neuropsychological and motor function tests, and neuroimaging studies. The power of plasma α-synuclein level, MDQ, and SMDCS for discriminating DLB from non-demented controls (NC) or AD were compared.

Results: Overall, 121 participants diagnosed as 58 DLB, 31 AD, and 31 NC were enrolled. Patients with DLB had significantly higher mean plasma α-synuclein level (0.24 ± 0.32 pg/ml) compared to the NC group (0.08 ± 0.05 pg/ml) and the AD group (0.08 ± 0.05 pg/ml). The DLB group demonstrated higher MDQ (2.95 ± 1.60) compared to the NC (0.42 ± 0.98) or AD (0.44 ± 0.99) groups. The sensitivity/specificity of plasma α-synuclein level, MDQ, and SMDCS for differentiating DLB from non-DLB were 0.80/0.64, 0.83/0.89, and 0.88/0.93, respectively.

Conclusion: Both plasma α-synuclein and MDQ were significantly higher in patients with DLB compared to the NC or AD groups. The novel SMDCS, significantly improved accuracy for the clinical differentiation of DLB from AD or NC.

References

McKeith I, Boeve B, Dickson D, Halliday G, Taylor J, Weintraub D . Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017; 89(1):88-100. PMC: 5496518. DOI: 10.1212/WNL.0000000000004058. View

Lin W, Lu C, Chiu P, Yang S . Plasma Total α-Synuclein and Neurofilament Light Chain: Clinical Validation for Discriminating Parkinson's Disease from Normal Control. Dement Geriatr Cogn Disord. 2020; 49(4):401-409. DOI: 10.1159/000510325. View

Spies P, Melis R, Sjogren M, Olde Rikkert M, Verbeek M . Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disorders. J Alzheimers Dis. 2009; 16(2):363-9. DOI: 10.3233/JAD-2009-0955. View

Teng E, Hasegawa K, Homma A, Imai Y, Larson E, Graves A . The Cognitive Abilities Screening Instrument (CASI): a practical test for cross-cultural epidemiological studies of dementia. Int Psychogeriatr. 1994; 6(1):45-58; discussion 62. DOI: 10.1017/s1041610294001602. View

Kasuga K, Tokutake T, Ishikawa A, Uchiyama T, Tokuda T, Onodera O . Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2010; 81(6):608-10. DOI: 10.1136/jnnp.2009.197483. View

Ohrfelt A, Grognet P, Andreasen N, Wallin A, Vanmechelen E, Blennow K . Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?. Neurosci Lett. 2008; 450(3):332-5. DOI: 10.1016/j.neulet.2008.11.015. View

Barbour R, Kling K, Anderson J, Banducci K, Cole T, Diep L . Red blood cells are the major source of alpha-synuclein in blood. Neurodegener Dis. 2008; 5(2):55-9. DOI: 10.1159/000112832. View

Chiu P, Wei C, Hung G, Wu S . Motor Dysfunction Questionnaire and Dopamine Transporter Imaging Composite Scale Improve Differentiating Dementia With Lewy Bodies From Alzheimer's Disease With Motor Dysfunction. Front Aging Neurosci. 2021; 13:709215. PMC: 8385672. DOI: 10.3389/fnagi.2021.709215. View

Geser F, Wenning G, Poewe W, McKeith I . How to diagnose dementia with Lewy bodies: state of the art. Mov Disord. 2005; 20 Suppl 12:S11-20. DOI: 10.1002/mds.20535. View

10.

Ballard C, McKeith I, Burn D, Harrison R, OBrien J, Lowery K . The UPDRS scale as a means of identifying extrapyramidal signs in patients suffering from dementia with Lewy bodies. Acta Neurol Scand. 1998; 96(6):366-71. DOI: 10.1111/j.1600-0404.1997.tb00299.x. View

11.

Lawton M, Brody E . Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969; 9(3):179-86. View

12.

Chiu P, Hung G, Wei C, Tzeng R, Pai M . Freezing of Speech Single Questionnaire as a Screening Tool for Cognitive Dysfunction in Patients With Dementia With Lewy Bodies. Front Aging Neurosci. 2020; 12:65. PMC: 7199820. DOI: 10.3389/fnagi.2020.00065. View

13.

Noguchi-Shinohara M, Tokuda T, Yoshita M, Kasai T, Ono K, Nakagawa M . CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's disease. Brain Res. 2008; 1251:1-6. DOI: 10.1016/j.brainres.2008.11.055. View

14.

Zupancic M, Mahajan A, Handa K . Dementia with lewy bodies: diagnosis and management for primary care providers. Prim Care Companion CNS Disord. 2012; 13(5). PMC: 3267516. DOI: 10.4088/PCC.11r01190. View

15.

Lin C, Yang S, Horng H, Yang C, Chieh J, Chen H . Plasma α-synuclein predicts cognitive decline in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2017; 88(10):818-824. PMC: 5629933. DOI: 10.1136/jnnp-2016-314857. View

16.

Li Q, Mok S, Laughton K, McLean C, Cappai R, Masters C . Plasma alpha-synuclein is decreased in subjects with Parkinson's disease. Exp Neurol. 2007; 204(2):583-8. DOI: 10.1016/j.expneurol.2006.12.006. View

17.

Cummings J, Mega M, Gray K, Carusi D, Gornbein J . The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994; 44(12):2308-14. DOI: 10.1212/wnl.44.12.2308. View

18.

Wang C, Hung G, Wei C, Tzeng R, Chiu P . An Informant-Based Simple Questionnaire for Visuospatial Dysfunction Assessment in Dementia. Front Neurosci. 2020; 14:44. PMC: 7006475. DOI: 10.3389/fnins.2020.00044. View

19.

Nasreddine Z, Phillips N, Bedirian V, Charbonneau S, Whitehead V, Collin I . The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005; 53(4):695-9. DOI: 10.1111/j.1532-5415.2005.53221.x. View

20.

Zhu F, Li X, McGonigle D, Tang H, He Z, Zhang C . Analyze Informant-Based Questionnaire for The Early Diagnosis of Senile Dementia Using Deep Learning. IEEE J Transl Eng Health Med. 2020; 8:2200106. PMC: 6964964. DOI: 10.1109/JTEHM.2019.2959331. View